CVS Health (NYSE:CVS)‘s stock had its “buy” rating reissued by investment analysts at Raymond James Financial in a note issued to investors on Monday.

A number of other research firms have also issued reports on CVS. Royal Bank Of Canada assumed coverage on shares of CVS Health in a report on Tuesday, September 19th. They set an “outperform” rating and a $95.00 target price for the company. Jefferies Group upped their target price on shares of CVS Health from $82.00 to $86.00 and gave the stock a “hold” rating in a report on Friday, September 15th. Needham & Company LLC reaffirmed a “hold” rating on shares of CVS Health in a report on Sunday, September 10th. Wolfe Research lowered shares of CVS Health from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $89.00 to $82.00 in a report on Monday, August 14th. Finally, Robert W. Baird reissued an “outperform” rating and issued a $90.00 price objective on shares of CVS Health in a report on Monday, August 14th. One analyst has rated the stock with a sell rating, eight have given a hold rating and fifteen have given a buy rating to the stock. CVS Health has an average rating of “Buy” and an average target price of $86.35.

CVS Health (NYSE:CVS) traded down $3.43 during trading hours on Monday, reaching $71.69. 40,464,600 shares of the company’s stock were exchanged, compared to its average volume of 6,844,036. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.05 and a quick ratio of 0.55. The firm has a market capitalization of $76,095.96, a PE ratio of 13.16, a PEG ratio of 1.29 and a beta of 0.89. CVS Health has a 52 week low of $66.45 and a 52 week high of $84.72.

CVS Health (NYSE:CVS) last released its earnings results on Monday, November 6th. The pharmacy operator reported $1.50 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.49 by $0.01. CVS Health had a net margin of 2.77% and a return on equity of 16.96%. The business had revenue of $46.18 billion during the quarter, compared to analyst estimates of $46.17 billion. During the same quarter in the prior year, the firm earned $1.64 earnings per share. The company’s revenue for the quarter was up 3.5% compared to the same quarter last year. equities research analysts predict that CVS Health will post 5.9 earnings per share for the current year.

In related news, CFO David M. Denton sold 237,078 shares of the firm’s stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $79.65, for a total value of $18,883,262.70. Following the sale, the chief financial officer now owns 141,096 shares of the company’s stock, valued at $11,238,296.40. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Helena Foulkes sold 39,340 shares of the firm’s stock in a transaction that occurred on Friday, September 15th. The shares were sold at an average price of $81.88, for a total transaction of $3,221,159.20. Following the completion of the sale, the executive vice president now directly owns 84,337 shares in the company, valued at approximately $6,905,513.56. The disclosure for this sale can be found here. Insiders have sold 714,125 shares of company stock worth $58,119,381 in the last three months. Corporate insiders own 0.61% of the company’s stock.

A number of large investors have recently modified their holdings of the stock. Vanguard Group Inc. grew its position in shares of CVS Health by 1.4% during the second quarter. Vanguard Group Inc. now owns 76,557,597 shares of the pharmacy operator’s stock worth $6,159,825,000 after acquiring an additional 1,056,265 shares during the last quarter. FMR LLC grew its position in shares of CVS Health by 22.0% during the second quarter. FMR LLC now owns 30,150,634 shares of the pharmacy operator’s stock worth $2,425,920,000 after acquiring an additional 5,446,930 shares during the last quarter. Bank of America Corp DE grew its position in shares of CVS Health by 1.8% during the first quarter. Bank of America Corp DE now owns 22,411,957 shares of the pharmacy operator’s stock worth $1,759,338,000 after acquiring an additional 398,999 shares during the last quarter. Northern Trust Corp grew its position in shares of CVS Health by 5.5% during the second quarter. Northern Trust Corp now owns 15,618,081 shares of the pharmacy operator’s stock worth $1,256,631,000 after acquiring an additional 807,639 shares during the last quarter. Finally, Nordea Investment Management AB grew its position in shares of CVS Health by 8.4% during the second quarter. Nordea Investment Management AB now owns 14,154,922 shares of the pharmacy operator’s stock worth $1,138,905,000 after acquiring an additional 1,100,373 shares during the last quarter. 82.24% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “CVS Health (CVS) Receives Buy Rating from Raymond James Financial” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/05/cvs-health-cvs-receives-buy-rating-from-raymond-james-financial.html.

About CVS Health

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Analyst Recommendations for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corp and related companies with MarketBeat.com's FREE daily email newsletter.